182 related articles for article (PubMed ID: 37980111)
1. Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion.
Shirani A; Stuve O; Cross AH
Neurol Clin; 2024 Feb; 42(1):137-153. PubMed ID: 37980111
[TBL] [Abstract][Full Text] [Related]
2. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
6. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
8. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
9. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
10. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple sclerosis with anti-CD20 antibodies.
Barun B; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
[TBL] [Abstract][Full Text] [Related]
13. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
Jakimovski D; Weinstock-Guttman B; Zivadinov R
Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
[TBL] [Abstract][Full Text] [Related]
14. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.
Menge T; Dubey D; Warnke C; Hartung HP; Stüve O
Expert Rev Neurother; 2016 Oct; 16(10):1131-9. PubMed ID: 27552111
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
16. Two cases of meningitis associated with ocrelizumab therapy.
Theriault M; Solomon AJ
Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
18. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
Gibiansky E; Petry C; Mercier F; Günther A; Herman A; Kappos L; Hauser S; Yamamoto Y; Wang Q; Model F; Kletzl H
Br J Clin Pharmacol; 2021 Jun; 87(6):2511-2520. PubMed ID: 33202059
[TBL] [Abstract][Full Text] [Related]
19. Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).
Curran C; Vaitaitis G; Waid D; Volmer T; Alverez E; Wagner DH
J Neuroimmunol; 2023 Jan; 374():578008. PubMed ID: 36535240
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
